Skip to main content
Figure 4 | Journal of Translational Medicine

Figure 4

From: Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations

Figure 4

Western blot analysis of different BRAFV600E mutant cell lines. Cells were exposed for 24 hours to 5 μM vemurafenib, 10 mM metformin, or the combination. Phosphorylation was analyzed with antibodies against specific phosphor-proteins compared to their total proteins. Synergistic characteristics of the cell lines are indicated as + (slight synergy), ++ (significant synergy), - (slight antagonism), and - - (significant antagonism).

Back to article page